Trevi Therapeutics announced the pricing of an underwritten public offering of 11.6 million shares at $13 each, raising approximately $150 million before fees. The funds will support the development of Haduvio™, their investigational oral therapy for chronic cough in patients with idiopathic pulmonary fibrosis and other lung diseases. The offering includes a 30-day option for underwriters to buy an additional 1.74 million shares. The deal is expected to close around April 20, 2026, helping Trevi advance its clinical-stage biopharmaceutical programs.
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
ASUS has introduced two new Chromebooks in the US market: the budget-friendly CM15 laptop and the versatile CM32 Detachable 2-in-1 device. Both run on the MediaTek Kompanio 540 processor, offer up to 12 hours of battery life, and feature military-gra...
Slate Medicines, a biotech firm focused on migraine treatments, has appointed Mark W. Hahn to its Board of Directors. Hahn brings over 25 years of experience in life sciences, including leading companies through financial milestones and FDA approvals...
The global clinical trials market is projected to grow from $135.51 billion in 2026 to $176.32 billion by 2030, at a CAGR of 6.8%. Growth is fueled by advances in AI-enabled trial design, decentralized and hybrid trial platforms, and increasing deman...
California American Water and Sonoma County Fire District completed projects reducing wildfire risk around water facilities in Sonoma County. The efforts included clearing flammable vegetation near critical infrastructure like water storage tanks and...
